During the third day of a civil trial between Dr. Michael Joyner and Mayo Clinic, the president of Mayo Clinic Platform faced questions about calling Joyner mentally ill as he ...

AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today reported positive data in a year-end update from the ongoing Phase 2 clinical study ...

Year-end report discusses combination therapy’s Mechanism of Action activating both innate and adaptive immune responsesOCALA ...

Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded ...

Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients ...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the l ...